Skip to main content

    Candel Therapeutics (CADL) ratings reaffirmed by 4 firms after its earnings report

    GNG Research Market News

    By GNG Research

    Candel Therapeutics Inc (CADL) received rating reaffirmations from four firms from November 13, 2026 through November 16, 2026. Four bullish, zero neutral, zero bearish. No firm changed its rating.

    FirmRatingTier
    Canaccord GenuityBuybullish
    CitigroupBuybullish
    HC Wainwright & Co.Buybullish
    StifelBuybullish

    The past 90 days include six active firms, with six rating the stock bullish. 10 analysts set consensus price targets as of November 10, 2026, with a mean of $23.33, a median of $24.48 and a range of $15.15 to $30.45.

    For Q4 FY2026, analysts expect EPS of -$0.38 and revenue of $0. The next earnings report is scheduled for March 10, 2027.